-
1
-
-
0029146718
-
Diversity in cyclic nucleotide phosphodiesterase isoenzyme families
-
Manganiello VC, Murata T, Taira M, Belfrage P, Degerman E. Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Arch Biochem Biophys 1995; 322:1-13.
-
(1995)
Arch Biochem Biophys
, vol.322
, pp. 1-13
-
-
Manganiello, V.C.1
Murata, T.2
Taira, M.3
Belfrage, P.4
Degerman, E.5
-
2
-
-
0032544181
-
Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double- Blind trial
-
Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998; 98:678-686. (Pubitemid 28387495)
-
(1998)
Circulation
, vol.98
, Issue.7
, pp. 678-686
-
-
Dawson, D.L.1
Cutler, B.S.2
Meissner, M.H.3
Strandness Jr., D.E.4
-
3
-
-
0035963659
-
Analysis of the cilostazol safety database
-
Pratt CM. Analysis of the cilostazol safety database. Am J Cardiol 2001; 87:28D-33D.
-
(2001)
Am J Cardiol
, vol.87
-
-
Pratt, C.M.1
-
4
-
-
0031966371
-
Chronotropic effects of cilostazol, a new antithrombotic agent, in patients with bradyarrhythmias
-
DOI 10.1097/00005344-199804000-00010
-
Atarashi H, Endoh Y, Saitoh H, Kishida H, Hayakawa H. Chronotropic effects of cilostazol, a new antithrombotic agent, in patients with bradyarrhythmias. J Cardiovasc Pharmacol 1998; 31:534-539. (Pubitemid 28153129)
-
(1998)
Journal of Cardiovascular Pharmacology
, vol.31
, Issue.4
, pp. 534-539
-
-
Atarashi, H.1
Endoh, Y.2
Saitoh, H.3
Kishida, H.4
Hayakawa, H.5
-
5
-
-
77953809302
-
The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: Principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study - A randomized trial
-
Katakami N, Kim YS, Kawamori R, Yamasaki Y. The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study - a randomized trial. Circulation 2010; 121:2584-2591.
-
(2010)
Circulation
, vol.121
, pp. 2584-2591
-
-
Katakami, N.1
Kim, Y.S.2
Kawamori, R.3
Yamasaki, Y.4
-
6
-
-
0037389193
-
Effect of cilostazol on the ventricular escape rate and neurohumoral factors in patients with third-degree atrioventricular block
-
DOI 10.1378/chest.123.4.1161
-
Kodama-Takahashi K, Kurata A, Ohshima K, Yamamoto K, Uemura S, Watanabe S, et al. Effect of cilostazol on the ventricular escape rate and neurohumoral factors in patients with third-degree atrioventricular block. Chest 2003; 123:1161-1169. (Pubitemid 36444374)
-
(2003)
Chest
, vol.123
, Issue.4
, pp. 1161-1169
-
-
Kodama-Takahashi, K.1
Kurata, A.2
Ohshima, K.3
Yamamoto, K.4
Uemura, S.5
Watanabe, S.6
Iwata, T.7
-
7
-
-
0037388986
-
Cilostazol: An 'intermittent claudication' remedy for the management of third-degree AV block
-
Madias JE. Cilostazol: an 'intermittent claudication' remedy for the management of third-degree AV block. Chest 2003; 123:979-982.
-
(2003)
Chest
, vol.123
, pp. 979-982
-
-
Madias, J.E.1
-
8
-
-
0036017528
-
Rapid ventricular tachycardias associated with cilostazol use
-
Gamssari F, Mahmood H, Ho JS, Villareal RP, Liu B, Rasekh A, et al. Rapid ventricular tachycardias associated with cilostazol use. Tex Heart Inst J 2002; 29:140-142. (Pubitemid 34627579)
-
(2002)
Texas Heart Institute Journal
, vol.29
, Issue.2
, pp. 140-142
-
-
Gamssari, F.1
Mahmood, H.2
Ho, J.S.3
Villareal, R.P.4
Liu, B.5
Rasekh, A.6
Garcia, E.7
Massumi, A.8
-
9
-
-
0033931498
-
Effects of cilostazol on heart rate and its variation patients with atrial fibrillation associated with bradycardia
-
Toyonaga S, Nakatsu T, Murakami T, Kusachi S, Mashima K, Tominaga Y, et al. Effects of cilostazol on heart rate and its variation in patients with atrial fibrillation associated with bradycardia. J Cardiovasc Pharmacol Ther 2000; 5:183-191. (Pubitemid 30483495)
-
(2000)
Journal of Cardiovascular Pharmacology and Therapeutics
, vol.5
, Issue.3
, pp. 183-191
-
-
Toyonaga, S.1
Nakatsu, T.2
Murakami, T.3
Kusachi, S.4
Mashima, K.5
Tominaga, Y.6
Yamane, S.7
Uesugi, T.8
Kanai, H.9
Tsuji, T.10
-
10
-
-
0035122176
-
Effects of cilostazol in patients with bradycardiac atrial fibrillation
-
Kishida M, Watanabe K, Tsuruoka T. Effects of cilostazol in patients with bradycardiac atrial fibrillation. J Cardiol 2001; 37:27-33. (Pubitemid 32148163)
-
(2001)
Journal of Cardiology
, vol.37
, Issue.1
, pp. 27-33
-
-
Kishida, M.1
Watanabe, K.2
Tsuruoka, T.3
-
11
-
-
0034773909
-
Effects of cilostazol on heart rate and its variability in patients with sick sinus syndrome
-
Ueda H, Nakatsu T, Murakami T, Kusachi S, Tominaga Y, Yamane S, et al. Effects of cilostazol on heart rate and its variability in patients with sick sinus syndrome. Clin Drug Invest 2001; 21:605-612. (Pubitemid 32937979)
-
(2001)
Clinical Drug Investigation
, vol.21
, Issue.9
, pp. 605-612
-
-
Tsuji, T.1
Ueda, H.2
Nakatsu, T.3
Murakami, T.4
Kusachi, S.5
Tominaga, Y.6
Yamane, S.7
Uesugi, T.8
Komatsubara, I.9
Iwabu, A.10
-
12
-
-
0035996742
-
Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome
-
Tsuchiya T, Ashikaga K, Honda T, Arita M. Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2002; 13:698-701. (Pubitemid 34774909)
-
(2002)
Journal of Cardiovascular Electrophysiology
, vol.13
, Issue.7
, pp. 698-701
-
-
Tsuchiya, T.1
Ashikaga, K.2
Honda, T.3
Arita, M.4
-
13
-
-
0027322458
-
Effects of vesnarinone on morbidity and mortality in patients with heart failure
-
DOI 10.1056/NEJM199307153290301
-
Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med 1993; 329:149-155. (Pubitemid 23195734)
-
(1993)
New England Journal of Medicine
, vol.329
, Issue.3
, pp. 149-155
-
-
Feldman, A.M.1
Bristow, M.R.2
Parmley, W.W.3
Carson, P.E.4
Pepine, C.J.5
Gilbert, E.M.6
Strobeck, J.E.7
Hendrix, G.H.8
Powers, E.R.9
Bain, R.P.10
White, B.G.11
-
14
-
-
0026072848
-
Effect of oral milrinone on mortality in severe chronic heart failure
-
The PROMISE Study Research Group
-
Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, Di Bianco R, Zeldis SM, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325:1468-1475.
-
(1991)
N Engl J Med
, vol.325
, pp. 1468-1475
-
-
Packer, M.1
Carver, J.R.2
Rodeheffer, R.J.3
Ivanhoe, R.J.4
Di Bianco, R.5
Zeldis, S.M.6
-
15
-
-
38649119141
-
Long-term safety of cilostazol in patients with peripheral artery disease: The CASTLE study (Cilostazol: A study in long-term effects)
-
Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: a study in long-term effects). J Vasc Surg 2008; 47:330-336.
-
(2008)
J Vasc Surg
, vol.47
, pp. 330-336
-
-
Hiatt, W.R.1
Money, S.R.2
Brass, E.P.3
-
16
-
-
0032830573
-
Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells
-
DOI 10.1097/00005344-199910000-00004
-
Cone J, Wang S, Tandon N, Fong M, Sun B, Sakurai K, et al. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J Cardiovasc Pharmacol 1999; 34:497-504. (Pubitemid 29446916)
-
(1999)
Journal of Cardiovascular Pharmacology
, vol.34
, Issue.4
, pp. 497-504
-
-
Cone, J.1
Wang, S.2
Tandon, N.3
Fong, M.4
Sun, B.5
Sakurai, K.6
Yoshitake, M.7
Kambayashi, J.-I.8
Liu, Y.9
-
17
-
-
0035544829
-
Cilostazol (Pletal): A dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake
-
Liu Y, Shakur Y, Yoshitake M, Kambayashi JJ. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev 2001; 19:369-386. (Pubitemid 34260705)
-
(2001)
Cardiovascular Drug Reviews
, vol.19
, Issue.4
, pp. 369-386
-
-
Liu, Y.1
Shakur, Y.2
Yoshitake, M.3
Kambayashi, J.-I.4
-
18
-
-
0036999131
-
Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart
-
DOI 10.1023/A:1022186402442
-
Shakur Y, Fong M, Hensley J, Cone J, Movsesian MA, Kambayashi J, et al. Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart. Cardiovasc Drugs Ther 2002; 16:417-427. (Pubitemid 36255742)
-
(2002)
Cardiovascular Drugs and Therapy
, vol.16
, Issue.5
, pp. 417-427
-
-
Shakur, Y.1
Fong, M.2
Hensley, J.3
Cone, J.4
Movsesian, M.A.5
Kambayashi, J.-I.6
Yoshitake, M.7
Liu, Y.8
-
19
-
-
0034770840
-
Interplay between inhibition of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to treat intermittent claudication
-
DOI 10.1097/00005344-200111000-00014
-
Wang S, Cone J, Fong M, Yoshitake M, Kambayashi J, Liu Y. Interplay between inhibition of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to treat intermittent claudication. J Cardiovasc Pharmacol 2001; 38:775-783. (Pubitemid 32983284)
-
(2001)
Journal of Cardiovascular Pharmacology
, vol.38
, Issue.5
, pp. 775-783
-
-
Wang, S.1
Cone, J.2
Fong, M.3
Yoshitake, M.4
Kambayashi, J.-I.5
Liu, Y.6
-
20
-
-
0033977303
-
Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21
-
Hayashi S, Morishita R, Matsushita H, Nakagami H, Taniyama Y, Nakamura T, et al. Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. Hypertension 2000; 35:237-243. (Pubitemid 30054179)
-
(2000)
Hypertension
, vol.35
, Issue.1 II
, pp. 237-243
-
-
Hayashi, S.-I.1
Morishita, R.2
Matsushita, H.3
Nakagami, H.4
Taniyama, Y.5
Nakamura, T.6
Aoki, M.7
Yamamoto, K.8
Higaki, J.9
Ogihara, T.10
-
21
-
-
0141885183
-
Cilostazol as a unique antithrombotic agent
-
DOI 10.2174/1381612033453910
-
Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F. Cilostazol as a unique antithrombotic agent. Curr Pharm Des 2003; 9:2289-2302. (Pubitemid 37236353)
-
(2003)
Current Pharmaceutical Design
, vol.9
, Issue.28
, pp. 2289-2302
-
-
Kambayashi, J.1
Liu, Y.2
Sun, B.3
Shakur, Y.4
Yoshitake, M.5
Czerwiec, F.6
-
22
-
-
20144384243
-
Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F
-
Kim MJ, Park KG, Lee KM, Kim HS, Kim SY, Kim CS, et al. Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F. Hypertension 2005; 45:552-556.
-
(2005)
Hypertension
, vol.45
, pp. 552-556
-
-
Kim, M.J.1
Park, K.G.2
Lee, K.M.3
Kim, H.S.4
Kim, S.Y.5
Kim, C.S.6
-
23
-
-
0038199678
-
Effect of cilostazol on vasomotor reactivity in patients with vasospastic angina pectoris
-
DOI 10.1016/S0002-9149(03)00458-2
-
Watanabe K, Ikeda S, Komatsu J, Inaba S, Suzuki J, Sueda S, et al. Effect of cilostazol on vasomotor reactivity in patients with vasospastic angina pectoris. Am J Cardiol 2003; 92:21-25. (Pubitemid 36782303)
-
(2003)
American Journal of Cardiology
, vol.92
, Issue.1
, pp. 21-25
-
-
Watanabe, K.1
Ikeda, S.2
Komatsu, J.3
Inaba, S.4
Suzuki, J.5
Sueda, S.6
Funada, J.-I.7
Kitakaze, M.8
Sekiya, M.9
-
25
-
-
33748446380
-
Roles of cardiac ryanodine receptor in heart failure and sudden cardiac death
-
DOI 10.1016/j.ijcard.2005.11.106, PII S0167527306001525
-
Phrommintikul A, Chattipakorn N. Roles of cardiac ryanodine receptor in heart failure and sudden cardiac death. Int J Cardiol 2006; 112:142-152. (Pubitemid 44353799)
-
(2006)
International Journal of Cardiology
, vol.112
, Issue.2
, pp. 142-152
-
-
Phrommintikul, A.1
Chattipakorn, N.2
-
26
-
-
0020605971
-
Evaluation of a new bipyridine inotropic agent - Milrinone - in patients with severe congestive heart failure
-
Baim DS, McDowell AV, Cherniles J, Monrad ES, Parker JA, Edelson J, et al. Evaluation of a new bipyridine inotropic agent - milrinone - in patients with severe congestive heart failure. N Engl J Med 1983; 309:748-756. (Pubitemid 13004282)
-
(1983)
New England Journal of Medicine
, vol.309
, Issue.13
, pp. 748-756
-
-
Baim, D.S.1
McDowell, A.V.2
Cherniles, J.3
-
27
-
-
0018246273
-
Hemodynamic assessment of amrinone. A new inotropic agent
-
Benotti JR, Grossman W, Braunwald E, Davolos DD, Alousi AA. Hemodynamic assessment of amrinone. A new inotropic agent. N Engl J Med 1978; 299:1373-1377. (Pubitemid 9092478)
-
(1978)
New England Journal of Medicine
, vol.299
, Issue.25
, pp. 1373-1377
-
-
Benotti, J.R.1
Grossman, W.2
Braunwald, E.3
-
28
-
-
0022001187
-
Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside
-
Jaski BE, Fifer MA, Wright RF, Braunwald E, Colucci WS. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. J Clin Invest 1985; 75:643-649. (Pubitemid 15142075)
-
(1985)
Journal of Clinical Investigation
, vol.75
, Issue.2
, pp. 643-649
-
-
Jaski, B.E.1
Fifer, M.A.2
Wright, R.F.3
-
29
-
-
0023257748
-
Acute hemodynamic and hormonal effects of CI-930, a new phosphodiesterase inhibitor, in severe congestive heart failure
-
DOI 10.1016/0002-9149(87)90919-2
-
Murali S, Uretsky BF, Valdes AM, Kolesar JA, Reddy PS. Acute hemodynamic and hormonal effects of CI-930, a new phosphodiesterase inhibitor, in severe congestive heart failure. Am J Cardiol 1987; 59:1356-1360. (Pubitemid 17093820)
-
(1987)
American Journal of Cardiology
, vol.59
, Issue.15
, pp. 1356-1360
-
-
Murali, S.1
Uretsky, B.F.2
Valdes, A.M.3
-
30
-
-
0025811327
-
Hemodynamic and neuroendocrine response to acute administration of the phosphodiesterase inhibitor BM14.478 in patients with congestive heart failure
-
Rauch B, Zimmermann R, Kapp M, Haass M, VonMolitor S, Smolarz A, et al. Hemodynamic and neuroendocrine response to acute administration of the phosphodiesterase inhibitor BM14.478 in patients with congestive heart failure. Clin Cardiol 1991; 14:386-395.
-
(1991)
Clin Cardiol
, vol.14
, pp. 386-395
-
-
Rauch, B.1
Zimmermann, R.2
Kapp, M.3
Haass, M.4
VonMolitor, S.5
Smolarz, A.6
-
31
-
-
0020533858
-
Long-term therapy with a new cardiotonic agent, WIN 47203: Drug-dependent improvement in cardiac performance and progression of the underlying disease
-
Sinoway LS, Maskin CS, Chadwick B, Forman R, Sonnenblick EH, Le Jemtel TH. Long-term therapy with a new cardiotonic agent, WIN 47203: drug-dependent improvement in cardiac performance and progression of the underlying disease. J Am Coll Cardiol 1983; 2:327-331. (Pubitemid 13078799)
-
(1983)
Journal of the American College of Cardiology
, vol.2
, Issue.2
, pp. 327-331
-
-
Sinoway, L.S.1
Maskin, C.S.2
Chadwick, B.3
-
33
-
-
0024537314
-
Electrophysiology of phosphodiesterase inhibitors
-
Naccarelli GV, Goldstein RA. Electrophysiology of phosphodiesterase inhibitors. Am J Cardiol 1989; 63:35A-40A.
-
(1989)
Am J Cardiol
, vol.63
-
-
Naccarelli, G.V.1
Goldstein, R.A.2
-
34
-
-
0346334593
-
PDE3 Inhibition in Dilated Cardiomyopathy: Reasons to Reconsider
-
DOI 10.1016/S1071-9164(03)00135-0
-
Movsesian MA. PDE3 inhibition in dilated cardiomyopathy: reasons to reconsider. J Card Fail 2003; 9:475-480. (Pubitemid 38055657)
-
(2003)
Journal of Cardiac Failure
, vol.9
, Issue.6
, pp. 475-480
-
-
Movsesian, M.A.1
-
35
-
-
0032698819
-
Beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: Shifting the focus from inotropy to cyclic adenosine monophosphate
-
Movsesian MA. Beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: shifting the focus from inotropy to cyclic adenosine monophosphate. J Am Coll Cardiol 1999; 34:318-324.
-
(1999)
J Am Coll Cardiol
, vol.34
, pp. 318-324
-
-
Movsesian, M.A.1
-
36
-
-
0034949792
-
Combined phosphodiesterase inhibition and beta-blockade in the GII04313, decreases ischemia-induced arrhythmias in the rat
-
Carceles MD, Aleixandre F, Fuente T, Lopez-Vidal J, Laorden ML. Combined phosphodiesterase inhibition and beta-blockade in the GI104313, decreases ischemia-induced arrhythmias in the rat. Can J Anaesth 2001; 48:486-492. (Pubitemid 32591254)
-
(2001)
Canadian Journal of Anesthesia
, vol.48
, Issue.5
, pp. 486-492
-
-
Carceles, M.D.1
Aleixandre, F.2
Fuente, T.3
Lopez-Vidal, J.4
Laorden, M.L.5
-
37
-
-
0036233984
-
Novel use of a short-acting intravenous beta blocker in combination with inotropic therapy as a bridge to chronic oral beta blockade in patients with advanced heart failure
-
Hauptman PJ, Woods D, Prirzker MR. Novel use of a short-acting intravenous beta blocker in combination with inotropic therapy as a bridge to chronic oral beta blockade in patients with advanced heart failure. Clin Cardiol 2002; 25:247-249. (Pubitemid 34457370)
-
(2002)
Clinical Cardiology
, vol.25
, Issue.5
, pp. 247-249
-
-
Hauptman, P.J.1
Woods, D.2
Pritzker, M.R.3
-
38
-
-
0034878176
-
Carvedilol titration in patients with congestive heart failure receiving inotropic therapy
-
DOI 10.1067/mhj.2001.117605
-
Kumar A, Choudhary G, Antonio C, Just V, Jain A, Heaney L, et al. Carvedilol titration in patients with congestive heart failure receiving inotropic therapy. Am Heart J 2001; 142:512-515. (Pubitemid 32801637)
-
(2001)
American Heart Journal
, vol.142
, Issue.3
, pp. 512-515
-
-
Kumar, A.1
Choudhary, G.2
Antonio, C.3
Just, V.4
Jain, A.5
Heaney, L.6
Papp, M.A.7
-
39
-
-
0032080759
-
Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure
-
PII S0735109798000771
-
Shakar SF, Abraham WT, Gilbert EM, Robertson AD, Lowes BD, Zisman LS, et al. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol 1998; 31:1336-1340. (Pubitemid 128713123)
-
(1998)
Journal of the American College of Cardiology
, vol.31
, Issue.6
, pp. 1336-1340
-
-
Shakar, S.F.1
Abraham, W.T.2
Gilbert, E.M.3
Robertson, A.D.4
Lowes, B.D.5
Zisman, L.S.6
Ferguson, D.A.7
Bristow, M.R.8
-
40
-
-
28244461264
-
Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium
-
DOI 10.1074/jbc.M506760200
-
Hambleton R, Krall J, Tikishvili E, Honeggar M, Ahmad F, Manganiello VC, et al. Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium. J Biol Chem 2005; 280:39168-39174. (Pubitemid 41713868)
-
(2005)
Journal of Biological Chemistry
, vol.280
, Issue.47
, pp. 39168-39174
-
-
Hambleton, R.1
Krall, J.2
Tikishvili, E.3
Honeggar, M.4
Ahmad, F.5
Manganiello, V.C.6
Movsesian, M.A.7
-
41
-
-
0036282248
-
Modulation of SERCA: Implications for the failing human heart
-
Frank KF, Bolck B, Brixius K, Kranias EG, Schwinger RH. Modulation of SERCA: implications for the failing human heart. Basic Res Cardiol 2002; 97 (Suppl 1):I72-I78.
-
(2002)
Basic Res Cardiol
, vol.97
, Issue.SUPPL. 1
-
-
Frank, K.F.1
Bolck, B.2
Brixius, K.3
Kranias, E.G.4
Schwinger, R.H.5
-
42
-
-
0032865827
-
Human heart failure: CAMP stimulation of SR Ca(2+)-ATPase activity and phosphorylation level of phospholamban
-
Schmidt U, Hajjar RJ, Kim CS, Lebeche D, Doye AA, Gwathmey JK. Human heart failure: cAMP stimulation of SR Ca(2+)-ATPase activity and phosphorylation level of phospholamban. Am J Physiol 1999; 277:H474-H480.
-
(1999)
Am J Physiol
, vol.277
-
-
Schmidt, U.1
Hajjar, R.J.2
Kim, C.S.3
Lebeche, D.4
Doye, A.A.5
Gwathmey, J.K.6
-
43
-
-
24644524532
-
Mechanism of sudden cardiac death
-
Rubart M, Zipes DP. Mechanism of sudden cardiac death. J Clin Invest 2005; 115:2305-2315.
-
(2005)
J Clin Invest
, vol.115
, pp. 2305-2315
-
-
Rubart, M.1
Zipes, D.P.2
-
44
-
-
0025020589
-
Abnormal intracellular calcium handling, a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure
-
Morgan JP, Erny RE, Allen PD, Grossman W, Gwathmey JK. Abnormal intracellular calcium handling, a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure. Circulation 1990; 81:III21-III32.
-
(1990)
Circulation
, vol.81
-
-
Morgan, J.P.1
Erny, R.E.2
Allen, P.D.3
Grossman, W.4
Gwathmey, J.K.5
-
45
-
-
0034237310
-
Myocardial efficiency in stunned myocardium. Comparison of Ca(2+)-sensitization and PDE III-inhibition on energy consumption
-
Sunderdiek U, Korbmacher B, Gams E, Schipke JD. Myocardial efficiency in stunned myocardium. Comparison of Ca(2+)-sensitization and PDE III-inhibition on energy consumption. Eur J Cardiothorac Surg 2000; 18:83-89.
-
(2000)
Eur J Cardiothorac Surg
, vol.18
, pp. 83-89
-
-
Sunderdiek, U.1
Korbmacher, B.2
Gams, E.3
Schipke, J.D.4
-
46
-
-
0035984729
-
Reevaluating the role of phosphodiesterase inhibitors in the treatment of cardiovascular disease
-
Feldman AM, McNamara DM. Reevaluating the role of phosphodiesterase inhibitors in the treatment of cardiovascular disease. Clin Cardiol 2002; 25:256-262. (Pubitemid 34568582)
-
(2002)
Clinical Cardiology
, vol.25
, Issue.6
, pp. 256-262
-
-
Feldman, A.M.1
McNamara, D.M.2
-
47
-
-
0022481941
-
Electrophysiologic effects of milrinone in patients with congestive heart failure
-
DOI 10.1016/0002-9149(86)90847-7
-
Goldstein RA, Geraci SA, Gray EL, Rinkenberger RL, Dougherty AH, Naccarelli GV. Electrophysiologic effects of milrinone in patients with congestive heart failure. Am J Cardiol 1986; 57:624-628. (Pubitemid 16015950)
-
(1986)
American Journal of Cardiology
, vol.57
, Issue.8
, pp. 624-628
-
-
Goldstein, R.A.1
Geraci, S.A.2
Gray, E.L.3
-
48
-
-
8844274873
-
Clinical trials update from the Heart Failure Society of America: EMOTE, HERB-CHF, BEST genetic sub-study and RHYTHM-ICD
-
DOI 10.1016/j.ejheart.2004.10.003, PII S1388984204002806
-
Lalukota K, Cleland JG, Ingle L, Clark AL, Coletta AP. Clinical trials update from the Heart Failure Society of America: EMOTE, HERB-CHF, BEST genetic sub-study and RHYTHM-ICD. Eur J Heart Fail 2004; 6:953-955. (Pubitemid 39536312)
-
(2004)
European Journal of Heart Failure
, vol.6
, Issue.7
, pp. 953-955
-
-
Lalukota, K.1
Cleland, J.G.F.2
Ingle, L.3
Clark, A.L.4
Coletta, A.P.5
-
49
-
-
0033529402
-
Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty
-
Tsuchikane E, Fukuhara A, Kobayashi T, Kirino M, Yamasaki K, Kobayashi T, et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation 1999; 100:21-26. (Pubitemid 29297935)
-
(1999)
Circulation
, vol.100
, Issue.1
, pp. 21-26
-
-
Tsuchikane, E.1
Fukuhara, A.2
Kobayashi, T.3
Kirino, M.4
Yamasaki, K.5
Kobayashi, T.6
Izumi, M.7
Otsuji, S.8
Tateyama, H.9
Sakurai, M.10
Awata, N.11
-
51
-
-
0014000319
-
The chronotropic effect of adenine- and hypoxanthine derivatives on isolated rat hearts before and after removing the sino-auricular node
-
Versprille A. The chronotropic effect of adenine- and hypoxanthine derivatives on isolated rat hearts before and after removing the sino-auricular node. Pflugers Arch Gesamte Physiol Menschen Tiere 1966; 291:261-267.
-
(1966)
Pflugers Arch Gesamte Physiol Menschen Tiere
, vol.291
, pp. 261-267
-
-
Versprille, A.1
-
52
-
-
0020619188
-
Modulation of myocardial cyclic AMP and vulnerability to fibrillation in the rat heart
-
Lubbe WF, Nguyen T, West EJ. Modulation of myocardial cyclic AMP and vulnerability to fibrillation in the rat heart. Fed Proc 1983; 42:2460-2464. (Pubitemid 13043668)
-
(1983)
Federation Proceedings
, vol.42
, Issue.8
, pp. 2460-2464
-
-
Lubbe, W.F.1
Nguyen, T.2
West, E.J.3
-
53
-
-
39849087752
-
Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients - CIilostazol for Diabetic Patients in Drug-Eluting Stent (CIDES) Trial
-
DOI 10.1253/circj.72.35
-
Ahn Y, Jeong MH, Jeong JW, Kim KH, Ahn TH, Kang WC, et al. Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients: clilostazol for diabetic patients in drug-eluting stent (CIDES) trial. Circ J 2008; 72:35-39. (Pubitemid 351413323)
-
(2008)
Circulation Journal
, vol.72
, Issue.1
, pp. 35-39
-
-
Ahn, Y.1
Myung, H.J.2
Jong, W.J.3
Kye, H.K.4
Tae, H.A.5
Woong, C.K.6
Park, C.-G.7
Jong, H.K.8
Chae, I.-H.9
Chang, W.N.10
Hur, S.-H.11
Bae, J.-H.12
Ki, Y.K.13
Seok, K.O.14
-
54
-
-
70350717086
-
Stroke prevention by cilostazol in patients with atherothrombosis: Meta-analysis of placebo-controlled randomized trials
-
Uchiyama S, Demaerschalk BM, Goto S, Shinohara Y, Gotoh F, Stone WM, et al. Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials. J Stroke Cerebrovasc Dis 2009; 18:482-490.
-
(2009)
J Stroke Cerebrovasc Dis
, vol.18
, pp. 482-490
-
-
Uchiyama, S.1
Demaerschalk, B.M.2
Goto, S.3
Shinohara, Y.4
Gotoh, F.5
Stone, W.M.6
-
56
-
-
67649109740
-
Efficacy of triple anti-platelet therapy including cilostazol in acute myocardial infarction patients undergoing drug-eluting stent implantation
-
Park KH, Jeong MH, Lee MG, Ko JS, Lee SE, Kang WY, et al. Efficacy of triple anti-platelet therapy including cilostazol in acute myocardial infarction patients undergoing drug-eluting stent implantation. Korean Circ J 2009; 39:190-197.
-
(2009)
Korean Circ J
, vol.39
, pp. 190-197
-
-
Park, K.H.1
Jeong, M.H.2
Lee, M.G.3
Ko, J.S.4
Lee, S.E.5
Kang, W.Y.6
-
57
-
-
0017623853
-
Cardiac pacing and pacemaker. I: Indications for pacing bradyarrhythmias
-
Furman S. Cardiac pacing and pacemaker. I: Indications for pacing bradyarrhythmias. Am Heart J 1977; 93:523-530.
-
(1977)
Am Heart J
, vol.93
, pp. 523-530
-
-
Furman, S.1
-
58
-
-
12344277382
-
Role of permanent pacing to prevent atrial fibrillation: Science Advisory from the American Heart Association Council on Clinical Cardiology (Subcommittee on Electrocardiography and Arrhythmias) and the Quality of Care and Outcomes research interdisciplinary Working Group, in collaboration with the Heart Rhythm Society
-
DOI 10.1161/01.CIR.0000151800.84945.47
-
Knight BP, Gersh BJ, Carlson MD, Friedman PA, McNamara RL, Strickberger SA, et al. Role of permanent pacing to prevent atrial fibrillation: science advisory from the American Heart Association Council on Clinical Cardiology (Subcommittee on Electrocardiography and Arrhythmias) and the Quality of Care and Outcomes Research Interdisciplinary Working Group, in collaboration with the Heart Rhythm Society. Circulation 2005; 111:240-243. (Pubitemid 40139737)
-
(2005)
Circulation
, vol.111
, Issue.2
, pp. 240-243
-
-
Knight, B.P.1
Gersh, B.J.2
Carlson, M.D.3
Friedman, P.A.4
McNamara, R.L.5
Strickberger, S.A.6
Tse, H.F.7
Waldo, A.L.8
-
60
-
-
0021260740
-
Amrinone: Acute electrophysiologic and hemodynamic effects in patients with congestive heart failure
-
Naccarelli GV, Gray EL, Dougherty AH, Hanna JE, Goldstein RA. Amrinone: acute electrophysiologic and hemodynamic effects in patients with congestive heart failure. Am J Cardiol 1984; 54:600-604. (Pubitemid 14073252)
-
(1984)
American Journal of Cardiology
, vol.54
, Issue.6
, pp. 600-604
-
-
Naccarelli, G.V.1
Gray, E.L.2
Dougherty, A.H.3
-
61
-
-
0023780277
-
Ionic mechanisms of adenosine actions in pacemaker cells from rabbit heart
-
Belardinelli L, Giles WR, West A. Ionic mechanisms of adenosine actions in pacemaker cells from rabbit heart. J Physiol 1988; 405:615-633.
-
(1988)
J Physiol
, vol.405
, pp. 615-633
-
-
Belardinelli, L.1
Giles, W.R.2
West, A.3
-
62
-
-
0035997540
-
Potentiation of the negative dromotropic effect of adenosine by rapid heart rates: Possible ionic mechanism
-
DOI 10.1007/s00395-002-0354-y
-
Martynyuk AE, Zima A, Seubert CN, Morey TE, Belardinelli L, Dennis DM. Potentiation of the negative dromotropic effect of adenosine by rapid heart rates: possible ionic mechanism. Basic Res Cardiol 2002; 97:295-304. (Pubitemid 34808776)
-
(2002)
Basic Research in Cardiology
, vol.97
, Issue.4
, pp. 295-304
-
-
Martynyuk, A.E.1
Zima, A.2
Seubert, C.N.3
Morey, T.E.4
Belardinelli, L.5
Dennis, D.M.6
-
63
-
-
42149139071
-
Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarction
-
DOI 10.1139/Y08-005
-
Sanganalmath SK, Barta J, Takeda N, Kumamoto H, Dhalla NS. Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarction. Can J Physiol Pharmacol 2008; 86:180-189. (Pubitemid 351536449)
-
(2008)
Canadian Journal of Physiology and Pharmacology
, vol.86
, Issue.4
, pp. 180-189
-
-
Sanganalmath, S.K.1
Barta, J.2
Takeda, N.3
Kumamoto, H.4
Dhalla, N.S.5
-
64
-
-
77956884231
-
Cilostazol for prevention of secondary stroke (CSPS 2): An aspirin-controlled, double-blind, randomised non-inferiority trial
-
Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010; 9:959-968.
-
(2010)
Lancet Neurol
, vol.9
, pp. 959-968
-
-
Shinohara, Y.1
Katayama, Y.2
Uchiyama, S.3
Yamaguchi, T.4
Handa, S.5
Matsuoka, K.6
-
65
-
-
55449088781
-
Antiplatelet agents sarpogrelate and cilostazol affect experimentally-induced ventricular arrhythmias and mortality
-
Barta J, Sanganalmath SK, Kumamoto H, Takeda N, Edes I, Dhalla NS. Antiplatelet agents sarpogrelate and cilostazol affect experimentally-induced ventricular arrhythmias and mortality. Cardiovasc Toxicol 2008; 8:127-135.
-
(2008)
Cardiovasc Toxicol
, vol.8
, pp. 127-135
-
-
Barta, J.1
Sanganalmath, S.K.2
Kumamoto, H.3
Takeda, N.4
Edes, I.5
Dhalla, N.S.6
-
66
-
-
0033537470
-
'Brugada' syndrome: Clinical data and suggested pathophysiological mechanism
-
Alings M, Wilde A. 'Brugada' syndrome: clinical data and suggested pathophysiological mechanism. Circulation 1999; 99:666-673.
-
(1999)
Circulation
, vol.99
, pp. 666-673
-
-
Alings, M.1
Wilde, A.2
-
67
-
-
31444441326
-
The Brugada syndrome: An update
-
Shimizu W. The Brugada syndrome: an update. Intern Med 2005; 44:1224-1231.
-
(2005)
Intern Med
, vol.44
, pp. 1224-1231
-
-
Shimizu, W.1
-
69
-
-
21144469749
-
Link between SCN5A mutation and the Brugada syndrome ECG phenotype: Simulation study
-
DOI 10.1253/circj.69.567
-
Miyoshi S, Mitamura H, Fukuda Y, Tanimoto K, Hagiwara Y, Kanki H, et al. Link between SCN5A mutation and the Brugada syndrome ECG phenotype: simulation study. Circ J 2005; 69:567-575. (Pubitemid 40745730)
-
(2005)
Circulation Journal
, vol.69
, Issue.5
, pp. 567-575
-
-
Miyoshi, S.1
Mitamura, H.2
Fukuda, Y.3
Tanimoto, K.4
Hagiwara, Y.5
Kanki, H.6
Takatsuki, S.7
Murata, M.8
Miyazaki, T.9
Ogawa, S.10
-
70
-
-
3843151619
-
Brugada and long QT-3 syndromes: Two phenotypes of the sodium channel disease
-
DOI 10.1111/j.1542-474X.2004.93533.x
-
Khan IA, Nair CK. Brugada and long QT-3 syndromes: two phenotypes of the sodium channel disease. Ann Noninvasive Electrocardiol 2004; 9:280-289. (Pubitemid 39044081)
-
(2004)
Annals of Noninvasive Electrocardiology
, vol.9
, Issue.3
, pp. 280-289
-
-
Khan, I.A.1
Nair, C.K.2
-
71
-
-
33749070756
-
Brugada syndrome: Overview
-
Antzelevitch C, Brugada P, Brugada J, Brugada R, editors. Oxford: Blackwell-Futula
-
Antzelevitch C. Brugada syndrome: overview. In: Antzelevitch C, Brugada P, Brugada J, Brugada R, editors. The Brugada syndrome: from bench to bedside. Oxford: Blackwell-Futula; 2005. pp. 1-22.
-
(2005)
The Brugada Syndrome: From Bench to Bedside
, pp. 1-22
-
-
Antzelevitch, C.1
-
72
-
-
33750059805
-
Cellular mechanisms underlying the Brugada syndrome
-
Antzelevitch C, Brugada P, Brugada J, Brugada R, editors. Oxford: Blackwell-Futura
-
Antzelevitch CP, Fish JMD, Di Diego JMM. Cellular mechanisms underlying the Brugada syndrome. In: Antzelevitch C, Brugada P, Brugada J, Brugada R, editors. The Brugada syndrome: from bench to bedside. Oxford: Blackwell-Futura; 2005. pp. 52-77.
-
(2005)
The Brugada Syndrome: From Bench to Bedside
, pp. 52-77
-
-
Antzelevitch, C.P.1
Fish, J.M.D.2
Di Diego, J.M.M.3
-
73
-
-
77952026026
-
Cilostazol attenuates ventricular arrhythmia induction and improves defibrillation efficacy in swine
-
Kanlop N, Shinlapawittayatorn K, Sungnoon R, Weerateerangkul P, Chattipakorn S, Chattipakorn N. Cilostazol attenuates ventricular arrhythmia induction and improves defibrillation efficacy in swine. Can J Physiol Pharmacol 2010; 88:422-428.
-
(2010)
Can J Physiol Pharmacol
, vol.88
, pp. 422-428
-
-
Kanlop, N.1
Shinlapawittayatorn, K.2
Sungnoon, R.3
Weerateerangkul, P.4
Chattipakorn, S.5
Chattipakorn, N.6
-
74
-
-
0141986515
-
Heart rate variability in patients with Brugada syndrome in Thailand
-
DOI 10.1016/j.ehj.2003.06.005
-
Krittayaphong R, Veerakul G, Nademanee K, Kangkagate C. Heart rate variability in patients with Brugada syndrome in Thailand. Eur Heart J 2003; 24:1771-1778. (Pubitemid 37236867)
-
(2003)
European Heart Journal
, vol.24
, Issue.19
, pp. 1771-1778
-
-
Krittayaphong, R.1
Veerakul, G.2
Nademanee, K.3
Kangkagate, C.4
-
75
-
-
10744229848
-
Decreased nocturnal standard deviation of averaged NN intervals. An independent marker to identify patients at risk in the Brugada syndrome
-
Hermida JS, Leenhardt A, Cauchemez B, Denjoy I, Jarry G, Mizon F, et al. Decreased nocturnal standard deviation of averaged NN intervals. An independent marker to identify patients at risk in the Brugada syndrome. Eur Heart J 2003; 24:2061-2069.
-
(2003)
Eur Heart J
, vol.24
, pp. 2061-2069
-
-
Hermida, J.S.1
Leenhardt, A.2
Cauchemez, B.3
Denjoy, I.4
Jarry, G.5
Mizon, F.6
-
76
-
-
33644786312
-
Failure of cilostazol in the prevention of ventricular fibrillation in a patient with Brugada syndrome
-
DOI 10.1111/j.1540-8167.2005.00290.x
-
Abud A, Bagattin D, Goyeneche R, Becker C. Failure of cilostazol in the prevention of ventricular fibrillation in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2006; 17:210-212. (Pubitemid 43344873)
-
(2006)
Journal of Cardiovascular Electrophysiology
, vol.17
, Issue.2
, pp. 210-212
-
-
Abud, A.1
Bagattin, D.2
Goyeneche, R.3
Becker, C.4
-
77
-
-
33846625997
-
Atrial tachyarrhythmias in Brugada syndrome
-
Antzelevitch C, Brugada P, Brugada J, Brugada R, editors. Oxford: Blackwell-Futura
-
Borggrefe MMP, Schimpf RM, Gaita FM, Eckardt LM, Wolpert CM. Atrial tachyarrhythmias in Brugada syndrome. In: Antzelevitch C, Brugada P, Brugada J, Brugada R, editors. The Brugada syndrome: from bench to bedside. Oxford: Blackwell-Futura; 2005. pp. 178-83.
-
(2005)
The Brugada Syndrome: From Bench to Bedside
, pp. 178-183
-
-
Borggrefe, M.M.P.1
Schimpf, R.M.2
Gaita, F.M.3
Eckardt, L.M.4
Wolpert, C.M.5
-
78
-
-
0037120936
-
Atrial fibrillation and atrial vulnerability in patients with Brugada syndrome
-
DOI 10.1016/S0735-1097(02)02167-8, PII S0735109702021678
-
Morita H, Kusano-Fukushima K, Nagase S, Fujimoto Y, Hisamatsu K, Fujio H, et al. Atrial fibrillation and atrial vulnerability in patients with Brugada syndrome. J Am Coll Cardiol 2002; 40:1437-1444. (Pubitemid 35192869)
-
(2002)
Journal of the American College of Cardiology
, vol.40
, Issue.8
, pp. 1437-1444
-
-
Morita, H.1
Kusano-Fukushima, K.2
Nagase, S.3
Fujimoto, Y.4
Hisamatsu, K.5
Fujio, H.6
Haraoka, K.7
Kobayashi, M.8
Morita, S.T.9
Nakamura, K.10
Emori, T.11
Matsubara, H.12
Hina, K.13
Kita, T.14
Fukatani, M.15
Ohe, T.16
|